|
1
|
Varshavsky A: The ubiquitin system. Trends
Biochem Sci. 22:383–387. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ciechanover A: The ubiquitin-proteasome
pathway: On protein death and cell life. EMBO J. 17:7151–7160.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hershko A and Ciechanover A: The ubiquitin
system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Voges D, Zwickl P and Baumeister W: The
26S proteasome: A molecular machine designed for controlled
proteolysis. Annu Rev Biochem. 68:1015–1068. 1999. View Article : Google Scholar
|
|
5
|
Hershko A, Ciechanover A and Varshavsky A:
Basic Medical Research Award. The ubiquitin system. Nat Med.
6:1073–1081. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ciechanover A and Schwartz AL:
Ubiquitin-mediated degradation of cellular proteins in health and
disease. Hepatology. 35:3–6. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naujokat C and Hoffmann S: Role and
function of the 26S proteasome in proliferation and apoptosis. Lab
Invest. 82:965–980. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee DH and Goldberg AL: Proteasome
inhibitors: Valuable new tools for cell biologists. Trends Cell
Biol. 8:397–403. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adams J, Palombella VJ, Sausville EA,
Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and
Elliott PJ: Proteasome inhibitors: A novel class of potent and
effective antitumor agents. Cancer Res. 59:2615–2622.
1999.PubMed/NCBI
|
|
10
|
Meng L, Mohan R, Kwok BH, Elofsson M, Sin
N and Crews CM: Epoxomicin, a potent and selective proteasome
inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl
Acad Sci USA. 96:10403–10408. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hideshima T, Richardson P, Chauhan D,
Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome
inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes
drug resistance in human multiple myeloma cells. Cancer Res.
61:3071–3076. 2001.PubMed/NCBI
|
|
12
|
Shah SA, Potter MW and Callery MP:
Ubiquitin proteasome inhibition and cancer therapy. Surgery.
131:595–600. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Adams J: Preclinical and clinical
evaluation of proteasome inhibitor PS-341 for the treatment of
cancer. Curr Opin Chem Biol. 6:493–500. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adams J: Proteasome inhibitors as new
anticancer drugs. Curr Opin Oncol. 14:628–634. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Almond JB and Cohen GM: The proteasome: A
novel target for cancer chemotherapy. Leukemia. 16:433–443. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garber K: On the eve of protein
destruction: Ubiquitin research begins to pay off. J Natl Cancer
Inst. 94:550–552. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hernandez AA and Roush WR: Recent advances
in the synthesis, design and selection of cysteine protease
inhibitors. Curr Opin Chem Biol. 6:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ling YH, Liebes L, Ng B, Buckley M,
Elliott PJ, Adams J, Jiang JD, Muggia FM and Perez-Soler R: PS-341,
a novel proteasome inhibitor, induces Bcl-2 phosphorylation and
cleavage in association with G2-M phase arrest and apoptosis. Mol
Cancer Ther. 1:841–849. 2002.PubMed/NCBI
|
|
19
|
Sakamoto KM: Ubiquitin-dependent
proteolysis: Its role in human diseases and the design of
therapeutic strategies. Mol Genet Metab. 77:44–56. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Smith DM, Wang Z, Kazi A, Li LH, Chan TH
and Dou QP: Synthetic analogs of green tea polyphenols as
proteasome inhibitors. Mol Med. 8:382–392. 2002.PubMed/NCBI
|
|
21
|
Yu R, Ren SG and Melmed S: Proteasome
inhibitors induce apoptosis in growth hormone- and
prolactin-secreting rat pituitary tumor cells. J Endocrinol.
174:379–386. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
LeBlanc R, Catley LP, Hideshima T, et al:
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in
vivo and prolongs survival in a murine model. Cancer Res.
62:4996–5000. 2002.PubMed/NCBI
|
|
23
|
Orlowski RZ, Stinchcombe TE, Mitchell BS,
et al: Phase I trial of the proteasome inhibitor PS-341 in patients
with refractory hematologic malignancies. J Clin Oncol.
20:4420–4427. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ohkawa K, Asakura T, Aoki K, Shibata S,
Minami J, Fujiwara C, Sai T, Marushima H and Kuzuu H: Establishment
and some characteristics of epoxomicin (a proteasome inhibitor)
resistant variants of the human squamous cell carcinoma cell line,
A431. Int J Oncol. 24:425–433. 2004.PubMed/NCBI
|
|
25
|
Duband JL, Monier F, Delannet M and
Newgreen D: Epithelium-mesenchyme transition during neural crest
development. Acta Anat (Basel). 154:63–78. 1995. View Article : Google Scholar
|
|
26
|
Viebahn C: Epithelio-mesenchymal
transformation during formation of the mesoderm in the mammalian
embryo. Acta Anat (Basel). 154:79–97. 1995. View Article : Google Scholar
|
|
27
|
Birchmeier W and Behrens J: Cadherin
expression in carcinomas: Role in the formation of cell junctions
and the prevention of invasiveness. Biochim Biophys Acta.
1198:11–26. 1994.PubMed/NCBI
|
|
28
|
Bussemakers MJG, van Bokhoven A, Völler M,
Smit FP and Schalken JA: The genes for the calcium-dependent cell
adhesion molecules P- and E-cadherin are tandemly arranged in the
human genome. Biochem Biophys Res Commun. 203:1291–1294. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berx G, Cleton-Jansen AM, Nollet F, de
Leeuw WJ, van de Vijver M, Cornelisse C and van Roy F: E-cadherin
is a tumour/invasion suppressor gene mutated in human lobular
breast cancers. EMBO J. 14:6107–6115. 1995.PubMed/NCBI
|
|
30
|
Takeichi M: Cadherins in cancer:
Implications for invasion and metastasis. Curr Opin Cell Biol.
5:806–811. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Christofori G and Semb H: The role of the
cell-adhesion molecule E-cadherin as a tumour-suppressor gene.
Trends Biochem Sci. 24:73–76. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Batlle E, Sancho E, Francí C, Domínguez D,
Monfar M, Baulida J and García De Herreros A: The transcription
factor snail is a repressor of E-cadherin gene expression in
epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bolós V, Peinado H, Pérez-Moreno MA, Fraga
MF, Esteller M and Cano A: The transcription factor Slug represses
E-cadherin expression and induces epithelial to mesenchymal
transitions: A comparison with Snail and E47 repressors. J Cell
Sci. 116:499–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Perez-Moreno MA, Locascio A, Rodrigo I,
Dhondt G, Portillo F, Nieto MA and Cano A: A new role for E12/E47
in the repression of E-cadherin expression and
epithelial-mesenchymal transitions. J Biol Chem. 276:27424–27431.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Berx G, Raspé E, Christofori G, Thiery JP
and Sleeman JP: Pre-EMTing metastasis? Recapitulation of
morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Burk U, Schubert J, Wellner U, Schmalhofer
O, Vincan E, Spaderna S and Brabletz T: A reciprocal repression
between ZEB1 and members of the miR-200 family promotes EMT and
invasion in cancer cells. EMBO Rep. 9:582–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Korpal M and Kang Y: The emerging role of
miR-200 family of microRNAs in epithelial-mesenchymal transition
and cancer metastasis. RNA Biol. 5:115–119. 2008. View Article : Google Scholar
|
|
42
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Peter ME: Let-7 and miR-200 microRNAs:
Guardians against pluripotency and cancer progression. Cell Cycle.
8:843–852. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Spaderna S, Brabletz T and Opitz OG: The
miR-200 family: central player for gain and loss of the epithelial
phenotype. Gastroenterology. 136:1835–1837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lee Y, Ahn C, Han J, et al: The nuclear
RNase III Drosha initiates microRNA processing. Nature.
425:415–419. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yi R, Qin Y, Macara IG and Cullen BR:
Exportin-5 mediates the nuclear export of pre-microRNAs and short
hairpin RNAs. Genes Dev. 17:3011–3016. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hutvágner G, McLachlan J, Pasquinelli AE,
Bálint E, Tuschl T and Zamore PD: A cellular function for the
RNA-interference enzyme Dicer in the maturation of the let-7 small
temporal RNA. Science. 293:834–838. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wienholds E, Kloosterman WP, Miska E,
Alvarez-Saavedra E, Berezikov E, de Bruijn E, Horvitz HR, Kauppinen
S and Plasterk RH: MicroRNA expression in zebrafish embryonic
development. Science. 309:310–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yi R, O’Carroll D, Pasolli HA, Zhang Z,
Dietrich FS, Tarakhovsky A and Fuchs E: Morphogenesis in skin is
governed by discrete sets of differentially expressed microRNAs.
Nat Genet. 38:356–362. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
51
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang Q, Gumireddy K, Schrier M, et al:
The microRNAs miR-373 and miR-520c promote tumour invasion and
metastasis. Nat Cell Biol. 10:202–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tavazoie SF, Alarcón C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar
|
|
57
|
Akao Y, Nakagawa Y and Naoe T: let-7
microRNA functions as a potential growth suppressor in human colon
cancer cells. Biol Pharm Bull. 29:903–906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Calin GA, Dumitru CD, Shimizu M, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar
|
|
59
|
Johnson CD, Esquela-Kerscher A, Stefani G,
et al: The let-7 microRNA represses cell proliferation pathways in
human cells. Cancer Res. 67:7713–7722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Takamizawa J, Konishi H, Yanagisawa K, et
al: Reduced expression of the let-7 microRNAs in human lung cancers
in association with shortened postoperative survival. Cancer Res.
64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J and Tanaka T:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
He L, Thomson JM, Hemann MT, et al: A
microRNA polycistron as a potential human oncogene. Nature.
435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Voorhoeve PM, le Sage C, Schrier M, et al:
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in
testicular germ cell tumors. Cell. 124:1169–1181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bracken CP, Gregory PA, Kolesnikoff N,
Bert AG, Wang J, Shannon MF and Goodall GJ: A double-negative
feedback loop between ZEB1-SIP1 and the microRNA-200 family
regulates epithelial-mesenchymal transition. Cancer Res.
68:7846–7854. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Spaderna S, Schmalhofer O, Hlubek F, Jung
A, Kirchner T and Brabletz T: Epithelial-mesenchymal and
mesenchymal-epithelial transitions during cancer progression. Verh
Dtsch Ges Pathol. 91:21–28. 2007.
|
|
67
|
Cano A and Nieto MA: Non-coding RNAs take
centre stage in epithelial-to-mesenchymal transition. Trends Cell
Biol. 18:357–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gregory PA, Bracken CP, Bert AG and
Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal
transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Savagner P: Leaving the neighborhood:
Molecular mechanisms involved during epithelial-mesenchymal
transition. BioEssays. 23:912–923. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Brabletz T, Jung A, Reu S, Porzner M,
Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T: Variable
beta-catenin expression in colorectal cancers indicates tumor
progression driven by the tumor environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dvorak HF: Tumors: Wounds that do not
heal. Similarities between tumor stroma generation and wound
healing. N Engl J Med. 315:1650–1659. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Fuchs IB, Lichtenegger W, Buehler H,
Henrich W, Stein H, Kleine-Tebbe A and Schaller G: The prognostic
significance of epithelial-mesenchymal transition in breast cancer.
Anticancer Res. 22:3415–3419. 2002.
|
|
73
|
Huang HN, Chen SY, Hwang SM, et al:
miR-200c and GATA binding protein 4 regulate human embryonic stem
cell renewal and differentiation. Stem Cell Res (Amst). 12:338–353.
2014. View Article : Google Scholar
|
|
74
|
Moes M, Le Béchec A, Crespo I, Laurini C,
Halavatyi A, Vetter G, Del Sol A and Friederich E: A novel network
integrating a miRNA-203/SNAI1 feedback loop which regulates
epithelial to mesenchymal transition. PLoS One. 7:e354402012.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop - a motor of cellular plasticity in development and
cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hill L, Browne G and Tulchinsky E:
ZEB/miR-200 feedback loop: At the crossroads of signal transduction
in cancer. Int J Cancer. 132:745–754. 2013. View Article : Google Scholar
|
